Research Topics

A Oliver Sartor

Summary

Affiliation: Tulane University
Country: USA

Publications

  1. Sartor O, Coleman R, Nilsson S, Heinrich D, Helle S, O Sullivan J, et al. Effect of radium-223 dichloride on symptomatic skeletal events in patients with castration-resistant prostate cancer and bone metastases: results from a phase 3, double-blind, randomised trial. Lancet Oncol. 2014;15:738-46 pubmed publisher
    ..We assessed the effect of radium-223 compared with placebo in patients with castration-resistant prostate cancer and bone metastases...
  2. Crawford E, Petrylak D, Sartor O. Navigating the evolving therapeutic landscape in advanced prostate cancer. Urol Oncol. 2017;35S:S1-S13 pubmed publisher
    ..The treatment of advanced prostate cancer and the research related to biomarkers are discussed. ..
  3. Sartor O, Vogelzang N, Sweeney C, Fernandez D, Almeida F, Iagaru A, et al. Radium-223 Safety, Efficacy, and Concurrent Use with Abiraterone or Enzalutamide: First U.S. Experience from an Expanded Access Program. Oncologist. 2018;23:193-202 pubmed publisher
    ..Patients with more advanced disease were less likely to benefit from radium-223. Clinicians should consider baseline clinical characteristics and therapy sequence to provide the greatest clinical value to patients. ..

Locale

Collaborators

Detail Information

Publications3

  1. Sartor O, Coleman R, Nilsson S, Heinrich D, Helle S, O Sullivan J, et al. Effect of radium-223 dichloride on symptomatic skeletal events in patients with castration-resistant prostate cancer and bone metastases: results from a phase 3, double-blind, randomised trial. Lancet Oncol. 2014;15:738-46 pubmed publisher
    ..We assessed the effect of radium-223 compared with placebo in patients with castration-resistant prostate cancer and bone metastases...
  2. Crawford E, Petrylak D, Sartor O. Navigating the evolving therapeutic landscape in advanced prostate cancer. Urol Oncol. 2017;35S:S1-S13 pubmed publisher
    ..The treatment of advanced prostate cancer and the research related to biomarkers are discussed. ..
  3. Sartor O, Vogelzang N, Sweeney C, Fernandez D, Almeida F, Iagaru A, et al. Radium-223 Safety, Efficacy, and Concurrent Use with Abiraterone or Enzalutamide: First U.S. Experience from an Expanded Access Program. Oncologist. 2018;23:193-202 pubmed publisher
    ..Patients with more advanced disease were less likely to benefit from radium-223. Clinicians should consider baseline clinical characteristics and therapy sequence to provide the greatest clinical value to patients. ..